Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment

Abstract Background Pancreatic cancer (PC) first‐line therapy often consists of polychemotherapy regimens, but choosing a second‐line therapy after disease progression, especially following first‐line FOLFIRINOX, remains a clinical challenge. This study presents results from a large, multicenter, re...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Guido Giordano, Michele Milella, Matteo Landriscina, Francesca Bergamo, Giuseppe Tirino, Antonio Santaniello, Alberto Zaniboni, Enrico Vasile, Ferdinando De Vita, Giovanni Lo Re, Vanja Vaccaro, Elisa Giommoni, Donato Natale, Raffaele Conca, Daniele Santini, Luigi Maiorino, Gianni Sanna, Vincenzo Ricci, Aldo Iop, Vincenzo Montesarchio, Letizia Procaccio, Silvia Noventa, Roberto Bianco, Antonio Febbraro, Sara Lonardi, Giampaolo Tortora, Isabella Sperduti, Davide Melisi
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2024-06-01
Saila:	Cancer Medicine
Gaiak:	FOLFIRINOX gemcitabine nab‐paclitaxel pancreatic cancer prognostic model second‐line chemotherapy
Sarrera elektronikoa:	https://doi.org/10.1002/cam4.7345
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!